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Abstract
Background Treatment for both facial and truncal acne has not sufficiently been studied.
Objectives To evaluate the long-term safety and efficacy of trifarotene in both facial and truncal acne.
Methods In a multicentre, open-label, 52-week study, patients with moderate facial and truncal acne received tri-
farotene 50 lg/g cream (trifarotene). Assessments included local tolerability, safety, investigator and physician’s global
assessments (IGA, PGA) and quality of life (QOL). A validated QOL questionnaire was completed by the patient at Base-
line, Week 12, 26 and 52/ET.
Results Of 453 patients enrolled, 342 (75.5%) completed the study. Trifarotene-related treatment-emergent adverse
events (TEAEs) were reported in 12.6% of patients, and none was serious. Most related TEAEs were cutaneous and
occurred during the first 3 months. Signs and symptoms of local tolerability were mostly mild or moderate and severe
signs, and symptoms were reported for 2.2% to 7.1% of patients for the face and 2.5% to 5.4% for the trunk. Local irrita-
tion increased during the first week of treatment on the face and up to Weeks 2 to 4 on the trunk with both decreasing
thereafter. At Week 12, IGA and PGA success rates were 26.6% and 38.6%, respectively. Success rates increased to
65.1% and 66.9%, respectively at Week 52. Overall success (both IGA and PGA success in the same patient) was
57.9% at Week 52. At Week 52 visit, 92/171 (53.8%) patients who had completed their assessments had scores from
0 to 1 (i.e. no effect of acne on their QOL) vs. 47/208 (22.6%) patients at Baseline visit.
Conclusion In this 52-week study, trifarotene was safe, well tolerated and effective in moderate facial and truncal
acne.
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Introduction
Acne is estimated to affect 9.4% of the global population, mak-
ing it the eighth most prevalent disease worldwide.1 Although
typically a disease of adolescence, it also affects a significant pro-
portion of adults, including up to 22% of adult women.2–5 It
may persist for years with permanent consequences including
scarring, low self-esteem and embarrassment due to the visible
nature of these marks.6 Acne on the face is the most common,
and often the most visible form of the disease and clinical studies
has evaluated the efficacy of acne therapy on the face. However,
back and chest acne have been estimated to occur in 61% and
45% of acne patients, respectively.7 Until now, acne on the back
has received only little attention in clinical studies.
Facial and truncal acne are considered pathophysiologically
and clinically similar, with both locations presenting comparable
types of lesions, although it may be possible to treat acne in both
locations with similar therapeutic approaches.8,9 Even though
many topical and systemic treatments have been used in the past
to treat acne, none has been specifically developed and clinically
studied for the treatment of both facial and truncal acne.
Currently, topical retinoids are the mainstay of acne treat-
ment, with adapalene, tretinoin and tazarotene available in vari-
ous concentrations, formulations and combinations as well as
orally administered isotretinoin. Retinoids have a central role in
acne therapy because they inhibit the development of micro-
comedones, have anti-inflammatory and immunomodulatory
properties and reduce acne lesions.10 Thus, they are considered a
foundation of acne treatment. Retinoids can be combined with
other topical therapies such as benzoyl peroxide or topical
antibiotics, as well as systemic treatments including antibiotics
and or oral contraceptives in more severe cases.11,12
Trifarotene cream 50 lg/g cream (hereafter trifarotene, devel-
oped by Nestle Skin Health – Galderma) has shown in acne
strong anti-comedogenic, antipigmenting activity and anti-in-
flammatory properties in vivo.13 This represents a new genera-
tion of retinoids, with a RAR-c selectivity that is highly
expressed in the skin. It has a good in vivo metabolic stability in
cultured keratinocytes and is rapidly metabolized in human liver
microsomes, predicting an improved safety profile due to low
systemic levels. In the Rhino mouse model, trifarotene showed a
dose-dependent comedolytic activity that is fully efficacious at a
10-fold lower concentration than that for tazarotene 0.1% cream
to achieve similar results.13 No accumulation is expected with
long-term use.13,14
The primary objective of this study was to assess the long-
term safety of trifarotene for up to 52 weeks of treatment in
patients with both moderate facial acne and truncal acne. Sec-
ondary objectives were the efficacy of trifarotene for up to
52 weeks and patient-reported quality of life (QoL).
Patient selection and methods
This was a long-term, multicentre, open-label, non-comparative,
phase 3, safety and efficacy study in patients with moderate acne
on the face and trunk. The study was conducted between Febru-
ary 2015 and February 2017.
The study complied with all local legal requirements for the
conduct of a clinical study and was conducted in accordance
with good clinical practices and the Principles of the Declaration
of Helsinki. Prior to the inclusion of any patient, the study
received local ethics committee or local independent review
board approval. Patients provided written informed consent
before participation. The study was registered in the US Clini-
calTrials.gov register (Identifier n°: NCT02189629) and the
European clinical trials register (EudraCT n°: 2014-001755-23).
In total, 453 patients were to be enrolled at 32 sites in Europe
(18 sites) and the USA (14 sites). The study included patients
9 years of age or older at enrolment, with an Investigator Global
Assessment (IGA, for face) score of 3 (moderate) on a 5-point
scale (from 0 = clear to 4 = severe), ≥20 inflammatory lesions
and ≥25 non-inflammatory lesions on the face, a physician’s glo-
bal assessment (PGA, for trunk) score of 3 (moderate) on a 5-
point scale (from 0 = clear to 4 = severe), and ≥20 inflamma-
tory lesions and ≥20 non-inflammatory lesions on the trunk (ch-
est, shoulders, upper back, mid and lower back, if applicable).
All investigators and study personnel were harmonized to the
study-specific measurements.
After the first application of trifarotene at study site, patients
were instructed to apply for the first 12 weeks trifarotene at
home once daily in the evening after washing and drying the
skin. Patients were encouraged to use a non-comedogenic and
hypoallergenic moisturizer of their choice and were instructed
not to apply moisturizer one hour before or one hour after study
drug application. The investigator could reduce trifarotene
application frequency, if tolerability issues arose. If, during the
study, IGA and PGA met treatment success criteria, the protocol
instructed: (i) If a patient’s IGA = 0 and PGA = 0, treatment
was discontinued; however, the patient had to continue to
attend the scheduled study visits. (ii) If a patient’s IGA = 0 and
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a PGA ≥ 1, treatment was discontinued on the face only. These
patients were asked to continue to apply their treatment on the
truncal region. (iii) If a patient’s IGA was ≥1 and PGA = 0,
treatment was discontinued on the truncal region, and the
patient was instructed to continue to apply the treatment on the
face.
Local tolerability signs and symptoms including erythema,
scaling, dryness and stinging/burning were evaluated on a 4-
point scale [0 (none) to 3 (severe) at Baseline and at Weeks 12,
20, 26, 38 and 52/ET]. Assessments were conducted separately
for the face and trunk. Treatment-emergent adverse events
(TEAE) were assessed through the study period. A TEAE was
defined as an adverse event that occurred, or increased in sever-
ity, on or after the date of the first application of trifarotene.
TEAEs were summarized per quarter (Q), based on the study
day: 1 to 89 (Q1), 90 to 179 (Q2), 180 to 269 (Q3) and ≥270
(Q4).
Routine laboratory parameters (biochemistry, haematology
and urinalysis) and pregnancy tests, when appropriate were
monitored at defined time points during the study.
Efficacy parameters were assessed at Baseline and at Weeks 12,
20, 26, 38 and 52/ET. IGA was used to assess the face, and PGA
was used to assess the reachable areas of the upper truncal
region. For children aged 9–11 years who did not meet truncal
acne inclusion criteria at the Screening and Baseline visits, PGA
was performed at all planned scheduled visits. If, during the
study, acne appeared on the trunk, treatment with trifarotene
and tolerability assessments were begun at the investigator’s dis-
cretion; these data were evaluated in the safety analysis.
Overall treatment success was defined at a particular study
visit if a patient had an IGA or PGA score of ‘0’ (clear) or ‘1’ (al-
most clear) and at least a 2-grade improvement from Baseline,
depending of the anatomical area assessed.
Patients evaluated their facial acne improvement compared
with their baseline disease status at Weeks 12, 26 and 52/ET,
based on a 6-point scale (from 0 = complete improvement to
5 = worse).
The dermatology life quality index (DLQI) and the children-
DLQI (C-DLQI), for patients aged up to 16 years at Baseline,
were completed by each patient at Baseline and Weeks 12, 26
and 52/ET.15,16 The DLQI/C-DLQI measured the dermatology-
related limitations of functional ability on patients’ lives. The
questionnaires were conducted prior to any acne assessment by
the investigator, to avoid influencing the patient’s answers. The
higher the score (ranging from 0 to 30), the more the QOL was
impaired.
For statistical analysis purposes, ‘Baseline’ evaluations were
defined as the last measurements prior to the first applica-
tion of trifarotene. No inferential statistical analysis was
planned. All data were summarized descriptively using
observed data. No imputation methods were used to impute
the missing values.
For summary statistics, categorical variables were summarized
by frequency and percentage for each response category. Contin-
uous variables were summarized using means and standard devi-
ations (mean  SD). All local tolerability and efficacy
endpoints, as well as DLQI/C-DLQI, were summarized by visit.
SAS version 9.4 or above was used for all statistical analyses.
Results
Study population
A total of 453 (99.6%) patients were enrolled and received tri-
farotene, and 348 (76.5%) completed the study. The most com-
mon reason for discontinuation was patient’s request 53
(11.6%). A total of 376 (83%) patients completed at least
180 days, and 342 (75.5%) patients completed 360 days. Details
about patient disposition are provided in Fig. 1. The mean
patient age was 18.3  6.6 years, ranging from 9 to 54 years.
Demographic and baseline characteristics for the PGA safety
population were similar to the IGA safety population.
Detailed demographic and baseline characteristics are pro-
vided in Table 1.
Local tolerability and safety
At Baseline, ˃80% of the patients did not exhibit any local toler-
ability signs/symptoms on the face and trunk. Table 2 provides
percentages of patients reporting local tolerability signs/symp-
toms by severity observed with trifarotene on the face and trunk.
The mean tolerability score, including worst score for each
parameter during the study period, is presented in Fig. 2 for the
face and in Fig. 3 for the trunk.
Overall, 468 TEAEs were reported in 218/453 (48.1%) patients
during the whole study period, of which 57 (12.6%) patients had
cutaneous AES related to trifarotene. Thirteen (2.9%) patients
had AES related to trifarotene leading to discontinuation. The
majority of all TEAEs that occurred during the first 3 months of
the study. Serious TEAEs occurred in 10 (2.2%) of the patients;
none were trifarotene-related.
The most common cutaneous trifarotene-related TEAEs were
pruritus [21 (4.6%) patients], irritation [19 (4.2%) patients] and
sunburn [8 (1.8%) patients]; these were mainly observed on
treated areas and were of mild severity. Severe trifarotene-related
TEAEs occurred in 3 (0.7%) different patients: application site
irritation, pruritus and erythema.
A total of 16 (3.5%) patients discontinued the study due to
TEAEs, among which 13 (2.9%) discontinued due to related
TEAEs. The latter were considered AESIs – 10 events were skin
irritation and three events were worsening of acne. All occurred
on the face and trunk during the first 3 months were related and
non-serious. All patients discontinued from the study and fol-
lowed up until complete resolution or stabilization.
Treatment-emergent adverse events were also analysed among
the subset of patients who extended the application of
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trifarotene to their middle and/or lower back and applied the
cream at least once during the study period in that area. The
safety profile in these patients (n = 231) was similar to that of
the overall safety population.
No clinically meaningful change in routine laboratory param-
eter values was observed during the study.
Efficacy
Both IGA and PGA success rates continuously improved over
time, IGA success rates increased from 26.6% at Week 12 to
65.1% at Week 52; PGA success rates increased from 38.6% at
Week 12 to 66.9% at Week 52. IGA and PGA success rates are
given in Fig. 4. Overall success (both IGA and PGA success in
the same patient) was 57.9% at Week 52 (Fig. 5).
The percentage of patients who reported a marked or com-
plete improvement of facial acne was 41.4% at Week 12, 54.8%
at Week 26 and 66.6% at Week 52.
Figure 6 provides visual support of improvement of severity of
acne on the face and trunk at different time points during the
study.
Quality of life
At Week 52 visit, 92/171 (53.8%) patients who had completed their
assessments had scores from 0 to 1 (i.e. no effect of acne on their
QOL) vs. 47/208 (22.6%) patients at Baseline visit (Table 3).
Discussion and conclusions
This 52-week long-term study assessed for the first time the
safety and efficacy of the first-in-class selective RAR-c agonist
trifarotene. Moreover, this study is the first to systematically
evaluate a treatment for both moderate facial acne and truncal
acne in a prospective long-term tolerability, safety and efficacy
study.
A total of 348 (76.5%) patients completed the study; a high
completion rate for a 52-week study, especially when considering
the age of the population (more than 63% of the patients were
younger than 18 years of age). Relatively few patients aged
between 9 and 11 years were enrolled. This was due the low
prevalence with truncal acne found in this group.
During this study, 103 trifarotene-related TEAEs were
reported in 57 (12.6%) of the patients. Only 16 (3.5%) of these
TEAEs led to study discontinuation, with a majority (2.9%)
occurring during the first quarter after treatment initiation. The
most common cutaneous TEAEs related to trifarotene were
application site pruritus [in 21 (4.6%) of the patients], applica-
tion site irritation [in 19 (4.2%) of the patients] and sunburn [in
8 (1.8%) of the patients]; all were observed on treated areas. As
observed with other retinoids, the majority of these local adverse
events occurred during the first weeks of treatment, subsiding
thereafter; all were mild or moderate in intensity.17–19 Local tol-
erability on the trunk was better than on the face. A possible
explanation could be that the epidermis of the back is thicker
than of the face. Facial and truncal skin are exposed to different
environmental challenges. Facial skin is more frequently exposed
to environmental sources of irritation and damage, and often
remains unprotected against external triggers such as UV light,
temperature and pollution, while the skin on the trunk is more
frequently exposed to heat, moisture and occlusion.9 The
Screen failures, N = 52
• Inclusion/exclusion criteria not met: n =35
• Subject’s request: n = 11
• Other: n = 6
Screened subjects
N = 507
Enrolled subjects
N = 455a
Completed subjects
N = 348
Subjects discontinued, N = 107
• Lack of efficacy: n = 4
• Adverse events: n = 16
• Subject’s request: n = 53
• Protocol violation: n = 4
• Lost to follow-up: n = 17
• Pregnancy: n = 1
• Other: n = 12
Subjects discontinued / visit
• Baseline: n = 2
• Week 1: n = 12
• Week 2: n = 7
• Week 4: n = 6
• Week 8: n = 28
• Week 12: n = 12
• Week 20: n = 16
• Week 26: n = 10
• Week 38: n = 6
• Week 52: n = 8
Figure 1 Patient disposition. Screened patients were those who had signed the ICF. Enrolled patients were those who did not fail
screening and were given trifarotene at Baseline visit. aOf the 455 patients enrolled, 453 were treated (i.e. two patients did not apply study
drug and returned the unused study drug).
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concomitant use of moisturizer facilitated management of ‘reti-
noid dermatitis’ as reported recently.20 To limit retinoid-related
side-effects, short contact therapy (SCT) was proposed for topi-
cal treatments with retinoids.21 To address this issue, SCT study
was performed during the development programme of
Table 1 Demographic and baseline characteristics
Safety population
(SAF, N = 453)
Safety PGA
population
(SAFT, N = 444)
Age (years)
Mean (SD) 18.3  6.6 18.4  6.5
Age group, n (%)
<18 years 286 (63.1) 277 (62.4)
≥18 years 167 (36.9) 167 (37.6)
9–11 years 18 (4.0) 9 (2.0)
Gender, n (%)
Male 227 (50.1) 227 (51.1)
Female 226 (49.9) 217 (48.9)
Race, n (%)
White 432 (95.4) 424 (95.5)
Black or African
American
12 (2.6) 11 (2.5)
Asian 3 (0.7) 3 (0.7)
American Indian or
Alaska Native
1 (0.2) 1 (0.2)
Native Hawaiian or
Other Pacific
Islander
3 (0.7) 3 (0.7)
Multiple 2 (0.4) 2 (0.5)
Other 0 0
Ethnicity, n (%)
Hispanic or Latino 47 (10.4) 44 (9.9)
Not Hispanic
or Latino
406 (89.6) 400 (90.1)
Skin phototype, n (%)
Type I 13 (2.9) 13 (2.9)
Type II 188 (41.5) 182 (41.0)
Type III 184 (40.6) 183 (41.2)
Type IV 53 (11.7) 52 (11.7)
Type V 7 (1.5) 7 (1.6)
Type VI 2 (0.4) 1 (0.2)
Missing 6 (1.3) 6 (1.4)
Baseline inflammatory facial lesion count
n 453 444
Mean (SD) 15.0 15.2
Baseline non-inflammatory facial lesion count
n 453 444
Mean (SD) 58.2  36.7 58.5  37.0
Baseline inflammatory truncal lesion count
n 446 444
Missing 7 0
Mean (SD) 43.4  28.6 43.5  28.5
Baseline non-inflammatory truncal lesion count
Missing 7 0
Mean (SD) 56.1  39.5 56.3  39.4
Safety Population (SAF): All patients that were randomized and applied the
study drug at least once. It includes all patients with facial acne/trunk acne
and facial acne/without truncal acne.
Safety PGA Population (SAFT): All patients that were randomized and
applied the study drug at least once on the trunk. It includes all patients with
facial acne/truncal acne.
Table 2 Local tolerability parameters worsened from Baseline
(worst post-baseline) on the face and trunk (SAFT Population)
Face (N = 453)
Erythema
n 449
Mild, n (%) 210 (46.8)
Moderate, n (%) 111 (24.7)
Severe, n (%) 10 (2.2)
Scaling
n 449
Mild, n (%) 210 (46.8)
Moderate, n (%) 131 (29.2)
Severe, n (%) 10 (2.2)
Dryness
n 449
Mild, n (%) 195 (43.4)
Moderate, n (%) 140 (31.2)
Severe, n (%) 26 (5.8)
Stinging/Burning
n 449
Mild, n (%) 169 (37.6)
Moderate, n (%) 95 (21.2)
Severe, n (%) 32 (7.1)
Trunk (N = 446)
Erythema
n 442
Mild, n (%) 131 (29.6)
Moderate, n (%) 76 (17.2)
Severe, n (%) 24 (5.4)
Scaling
n 442
Mild, n (%) 137 (31.0)
Moderate, n (%) 48 (10.9)
Severe, n (%) 11 (2.5)
Dryness
n 442
Mild, n (%) 152 (34.4)
Moderate, n (%) 63 (14.3)
Severe, n (%) 12 (2.7)
Stinging/Burning
n 442
Mild, n (%) 111 (25.1)
Moderate, n (%) 42 (9.5)
Severe, n (%) 21 (4.8)
Safety PGA Population (SAFT): All patients that were randomized and
applied the study drug at least once on the trunk. It includes all patients with
facial acne/truncal acne.
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trifarotene. Results from this pilot study showed a better tolera-
bility but reduced efficacy of trifarotene (unpublished results).
Overall success (IGA and PGA success in the same subject)
increased continuously with a greater acne improvement on the
trunk than on the face. At 52 weeks of treatment, 57.9% of the
patients experienced overall success, a significant therapeutic
benefit. The continued improvement, reaching high rates of
overall success (face and trunk clear or almost clear in the same
subject) over 52 weeks, is important for healthcare providers to
motivate and encourage patients to follow long-term topical
therapy with the expectation of further benefits.
The QOL of adults and children substantially improved over
the study period and was positively impacted by the improved
acne severity.
Patients had a high treatment compliance of 95.3% for both
face and trunk. The treatment regimen and manageable safety
profile might have played a role in the observed treatment com-
pliance, an observation reported by previous investigations.22
The open-label and non-comparative design of this study has
certain inherent limitations and biases. Nevertheless, the design
of this study was appropriate for the intended objectives, with
evaluation of local tolerance and safety of trifarotene in patients
with acne on both the face and trunk being the primary aim.
The results obtained during the study confirmed the primary
study objectives demonstrating that trifarotene is safe and well
tolerated. One yet unpublished phase 2 12-week study in
patients with moderate to severe acne evaluated three increasing
therapeutic concentrations of trifarotene cream (25, 50 and
100 lg/g) vs. vehicle and tazarotene 0.1% gel. The dose strength
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Figure 2 Local tolerability by visit: mean scores of signs and
symptoms on the face (SAF population). Safety Population (SAF):
All patients that were randomized and applied the study drug at
least once. It includes all patients with facial acne/trunk acne and
facial acne/without truncal acne. Local tolerability parameters
including erythema, scaling, dryness and stinging/burning were
evaluated at each visit on a 4-point scale (0 = none, 1 = mild,
2 = moderate and 3 = severe) at Baseline and at Weeks 12, 20,
26, 38 and 52/ET.
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Figure 3 Local tolerability by visit: mean scores of signs and
symptoms on the trunk (SAFT population). Safety PGA Population
(SAFT): All patients that were randomized and applied the study
drug at least once on the trunk. It includes all patients with facial
acne/truncal acne. Local tolerability parameters including ery-
thema, scaling, dryness and stinging/burning were evaluated at
each visit on a 4-point scale (0 = none, 1 = mild, 2 = moderate
and 3 = severe) at Baseline and at Weeks 12, 20, 26, 38 and 52/
ET.
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Figure 4 Evolution of the percent investigator's global assess-
ment and physician global assessment success rates at baseline
and weeks 12, 20, 26, 38 and 52 (SAFT population). Investigator's
Global Assessment (IGA) and Physician Global Assessment (PGA)
were scored on a 5-point scale (from 0 = clear to 4 = severe).
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Figure 5 Evolution of the overall percent investigator's global
assessment and physician global assessment success in the same
patient over 52 weeks (SAFT population). Overall treatment suc-
cess was defined at a particular study visit if the same patient had
an IGA/PGA score of “clear” or “almost clear” and at least a 2-
grade improvement from Baseline at any study visit.
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of trifarotene 50 lg/g was shown to be more effective than the
lower concentration (trifarotene 25 lg/g) and with regard to the
higher concentration (trifarotene 100 lg/g) in 2-point reduction
of Investigator’s Global Assessment (IGA) scores and per cent
decrease in inflammatory lesion count but less effective in reduc-
tion of total lesion count than trifarotene 100 lg/g cream.
Although both doses of 50 and 100 lg/g of trifarotene provided
a positive benefit/risk ratio in the treatment of acne vulgaris
when compared to vehicle, the superior safety and local tolera-
bility profile of trifarotene 50 lg/g cream over trifarotene
100 lg/g and tazarotene 0.1% gel argued in favour of carrying
this dose forward in phase 3. Two vehicle well-controlled, identi-
cal phase 3 studies in the target population further substantiated
the clinical benefit of trifarotene 50 lg/g cream of both facial
and truncal acne.23
In conclusion, in this 52-week study, once-daily application
of trifarotene 50 lg/g cream was safe, well tolerated and effective
in patients with moderate facial and truncal acne, providing
continuous improvement over time to patients. The present
results also support the acceptable safety profile of trifarotene.
Figure 6 Acne severity of two patients at different time points. Patient n°1: Face, Acne severity on the face decreased from an IGA score
of 3 to an IGA score of 1 at 12 weeks; Trunk, Acne severity on the trunk decreased from a PGA score of 3 to a PGA score of 2 at Week
12. Patient n°2: Face, Acne severity on the face decreased from an IGA score of 3 to an IGA score of 1 after 52 weeks.
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Moreover, this is the first comprehensive long-term study of
truncal acne using a validated methodology. Thus, this study
design could serve as a model for future investigations of this
largely ignored clinical condition.
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Table 3 Impact of acne on the patient's quality of life using the
Dermatology Life Quality Index and the Children Dermatology Life
Quality Index at Baseline and Week 52 (SAF Population)
Baseline Week 52
DLQI (N = 208) (N = 171)
No effect, n (%) 47 (22.6) 92 (53.8)
Small effect, n (%) 85 (40.9) 61 (35.7)
Moderate effect, n (%) 43 (20.7) 14 (8.2)
Very large effect, n (%) 33 (15.9) 4 (2.3)
Extremely large effect, n (%) 0 0
C-DLQI (N = 246) (N = 177)
No effect, n (%) 76 (30.9) 96 (54.2)
Small effect, n (%) 115 (46.7) 71 (40.1)
Moderate effect, n (%) 49 (19.9) 10 (5.6)
Very large effect, n (%) 6 (2.4) 0
Extremely large effect, n (%) 0 0
Safety Population (SAF): All patients that were randomized and applied the
study drug at least once. It includes all patients with facial acne/trunk acne
and facial acne/without truncal acne.
DLQI: Patients 17 years of age and older at Baseline visit; C-DLQI: Patients
aged ≤16 years at Baseline visit.
The meaning of the DLQI total scores was interpreted as follows: no effect (0
–1), small effect (2–6), moderate effect (7–12), very large effect (13–18) or
extremely large effect (19–30).
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